Drug intelligence / Profile preview

CT-P70

Development stage: Unknown
Lead developer: Celltrion
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CT-P70 is a novel antibody-drug conjugate (ADC) developed by Celltrion, targeting the cMET receptor in multiple solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, and gastric cancer. The drug utilizes a next-generation payload called PBX-7016, which was co-developed with Pinotbio. Preclinical studies have demonstrated potent tumor-suppressing effects even in tumors with low cMET expression compared to competing cMET-targeting ADCs. CT-P70 has shown a high therapeutic index and is designed for enhanced efficacy and safety[4][2][3].

Other names: CT-P70CT-P-70CT-P 70

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on CT-P70.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-P70.

Explore the full profile